Absence of dopamine receptor serum autoantibodies in schizophrenia patients with an acute disease episode

Schizophrenia Research

Volumn 158, Issue 1-3, 2014, Pages 272-274

  Müller, Ulf J ^a   Teegen, Bianca ^b   Probst, Christian ^b   Bernstein, Hans Gert ^a   Busse, Stefan ^a   Bogerts, Bernhard ^a,b   Schiltz, Kolja ^a,b   Stoecker, Winfried ^b   Steiner, Johann ^a,b  

^a OTTO VON GUERICKE UNIVERSITY   (Germany)

^b Institute for Experimental Immunology Affiliated to Euroimmun ^*  (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; DOPAMINE RECEPTOR; DOPAMINE RECEPTOR AUTOANTIBODY; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; UNCLASSIFIED DRUG;

ACUTE DISEASE; ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ANTIBODY TITER; DISEASE EXACERBATION; DOPAMINERGIC TRANSMISSION; HUMAN; IMMUNOFLUORESCENCE TEST; LETTER; NONHUMAN; PRIORITY JOURNAL; SCHIZOPHRENIA; ADULT; BLOOD; BORDERLINE PERSONALITY DISORDER; DEPRESSIVE DISORDER, MAJOR; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; HOSPITAL PATIENT; IMMUNOLOGY; MALE; PSYCHOLOGICAL RATING SCALE;

ACUTE DISEASE; ADULT; AUTOANTIBODIES; BORDERLINE PERSONALITY DISORDER; DEPRESSIVE DISORDER, MAJOR; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; INPATIENTS; MALE; PSYCHIATRIC STATUS RATING SCALES; RECEPTORS, DOPAMINE; SCHIZOPHRENIA;

EID: 84929940370     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2014.06.025     Document Type: Letter

References (15)

1. Coutinho E., Harrison P., Vincent A. Do neuronal autoantibodies cause psychosis? A neuroimmunological perspective. Biol. Psychiatry 2014, 75(4):269-275.
2. Dahm L., Ott C., Steiner J., Stepniak B., Teegen B., Saschenbrecker S., Hammer C., Borowski K., Begemann M., Lemke S., Rentzsch K., Probst C., Martens H., Wienands J., Spalletta G., Weissenborn K., Stocker W., Ehrenreich H. Seroprevalence of autoantibodies against brain antigens in health and disease. Ann. Neurol. 2014, 76(1):82-94.
3. Deakin J., Lennox B.R., Zandi M.S. Antibodies to the N-methyl-d-aspartate receptor and other synaptic proteins in psychosis. Biol. Psychiatry 2014, 75(4):284-291.
4. Ezeoke A., Mellor A., Buckley P., Miller B. A systematic, quantitative review of blood autoantibodies in schizophrenia. Schizophr. Res. 2013, 150(1):245-251.
5. Hammer C., Stepniak B., Schneider A., Papiol S., Tantra M., Begemann M., Siren A.L., Pardo L.A., Sperling S., Mohd Jofrry S., Gurvich A., Jensen N., Ostmeier K., Luhder F., Probst C., Martens H., Gillis M., Saher G., Assogna F., Spalletta G., Stocker W., Schulz T.F., Nave K.A., Ehrenreich H. Neuropsychiatric disease relevance of circulating anti-NMDA receptor autoantibodies depends on blood-brain barrier integrity. Mol. Psychiatry 2013, 10.1038/mp.2013.110.
6. Laruelle M. Schizophrenia: from dopaminergic to glutamatergic interventions. Curr. Opin. Pharmacol. 2014, 14C:97-102.
7. Lennox B.R., Coles A.J., Vincent A. Antibody-mediated encephalitis: a treatable cause of schizophrenia. Br. J. Psychiatry 2012, 200(2):92-94.
8. Miller B.J., Buckley P., Seabolt W., Mellor A., Kirkpatrick B. Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biol. Psychiatry 2011, 70(7):663-671.
9. Pollak T.A., McCormack R., Peakman M., Nicholson T.R., David A.S. Prevalence of anti-N-methyl-d-aspartate (NMDA) antibodies in patients with schizophrenia and related psychoses: a systematic review and meta-analysis. Psychol. Med. 2013, 1-13.
10. Stefansson H., Ophoff R.A., Steinberg S., Andreassen O.A., Cichon S., Rujescu D., Werge T., Pietilainen O.P., Mors O., Mortensen P.B., Sigurdsson E., Gustafsson O., Nyegaard M., Tuulio-Henriksson A., Ingason A., Hansen T., Suvisaari J., Lonnqvist J., Paunio T., Borglum A.D., Hartmann A., Fink-Jensen A., Nordentoft M., Hougaard D., Norgaard-Pedersen B., Bottcher Y., Olesen J., Breuer R., Moller H.J., Giegling I., Rasmussen H.B., Timm S., Mattheisen M., Bitter I., Rethelyi J.M., Magnusdottir B.B., Sigmundsson T., Olason P., Masson G., Gulcher J.R., Haraldsson M., Fossdal R., Thorgeirsson T.E., Thorsteinsdottir U., Ruggeri M., Tosato S., Franke B., Strengman E., Kiemeney L.A., Melle I., Djurovic S., Abramova L., Kaleda V., Sanjuan J., de Frutos R., Bramon E., Vassos E., Fraser G., Ettinger U., Picchioni M., Walker N., Toulopoulou T., Need A.C., Ge D., Yoon J.L., Shianna K.V., Freimer N.B., Cantor R.M., Murray R., Kong A., Golimbet V., Carracedo A., Arango C., Costas J., Jonsson E.G., Terenius L., Agartz I., Petursson H., Nothen M.M., Rietschel M., Matthews P.M., Muglia P., Peltonen L., St Clair D., Goldstein D.B., Stefansson K., Collier D.A. Common variants conferring risk of schizophrenia. Nature 2009, 460(7256):744-747.
11. Steiner J., Walter M., Glanz W., Sarnyai Z., Bernstein H.G., Vielhaber S., Kastner A., Skalej M., Jordan W., Schiltz K., Klingbeil C., Wandinger K.P., Bogerts B., Stoecker W. Increased prevalence of diverse N-methyl-d-aspartate glutamate receptor antibodies in patients with an initial diagnosis of schizophrenia: specific relevance of IgG NR1a antibodies for distinction from N-methyl-d-aspartate glutamate receptor encephalitis. JAMA Psychiatry 2013, 70(3):271-278.
12. Steiner J., Teegen B., Schiltz K., Bernstein H.G., Stoecker W., Bogerts B. Prevalence of N-methyl-d-aspartate receptor autoantibodies in the peripheral blood: healthy control samples revisited. JAMA Psychiatry 2014, 71(7):838-839.
13. Stoecker W., Saschenbrecker S., Rentzsch K., Komorowski L., Probst C. Autoantibody diagnostics in neurology using native and recombinant antigenic substrates. Nervenarzt 2013, 84(4):471-476.
14. Tanaka S., Matsunaga H., Kimura M., Tatsumi K., Hidaka Y., Takano T., Uema T., Takeda M., Amino N. Autoantibodies against four kinds of neurotransmitter receptors in psychiatric disorders. J. Neuroimmunol. 2003, 141(1-2):155-164.
15. von Kirchbach A., Fischer E.G., Kornhuber H.H. Failure to detect dopamine receptor IgG autoantibodies in sera of schizophrenic patients. Short note. J. Neural Transm. 1987, 70(1-2):175-179.